Announcement • Jun 30
Sirio Pharma Co., Ltd. to Report First Half, 2026 Results on Aug 29, 2026 Sirio Pharma Co., Ltd. announced that they will report first half, 2026 results on Aug 29, 2026 Declared Dividend • Jun 01
Dividend of CN¥0.13 announced Shareholders will receive a dividend of CN¥0.13. Ex-date: 5th June 2026 Payment date: 5th June 2026 Dividend yield will be 0.7%, which is lower than the industry average of 1.9%. Sustainability & Growth Dividend is covered by earnings (34% earnings payout ratio) but not covered by cash flows (103% cash payout ratio). The dividend has increased by an average of 8.7% per year over the past 6 years. However, payments have been volatile during that time. EPS is expected to grow by 217% over the next 3 years, which should provide support to the dividend and adequate earnings cover. Board Change • May 20
Less than half of directors are independent No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 5 experienced directors. 5 highly experienced directors. 3 independent directors (4 non-independent directors). Independent Director Guilong Zhu was the last independent director to join the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment. Announcement • Apr 24
Sirio Pharma Co., Ltd., Annual General Meeting, May 20, 2026 Sirio Pharma Co., Ltd., Annual General Meeting, May 20, 2026, at 15:00 China Standard Time. Location: The Company's Meeting Room, Shanghai China Announcement • Mar 31
Sirio Pharma Co., Ltd. to Report Q1, 2026 Results on Apr 24, 2026 Sirio Pharma Co., Ltd. announced that they will report Q1, 2026 results on Apr 24, 2026 Announcement • Dec 31
Sirio Pharma Co., Ltd. to Report Fiscal Year 2025 Results on Apr 24, 2026 Sirio Pharma Co., Ltd. announced that they will report fiscal year 2025 results on Apr 24, 2026 Announcement • Sep 30
Sirio Pharma Co., Ltd. to Report Q3, 2025 Results on Oct 29, 2025 Sirio Pharma Co., Ltd. announced that they will report Q3, 2025 results on Oct 29, 2025 Announcement • Jul 02
Sirio Pharma Co., Ltd. to Report First Half, 2025 Results on Aug 26, 2025 Sirio Pharma Co., Ltd. announced that they will report first half, 2025 results on Aug 26, 2025 Announcement • Apr 19
Sirio Pharma Co., Ltd. Proposes Final Cash Dividend for 2024 Sirio Pharma Co., Ltd. announced on 18 April 2025 the profit distribution proposal for 2024 as follows: Final cash dividend per 10 shares (tax included) of CNY 6.50000000. Announcement • Apr 18
Sirio Pharma Co., Ltd., Annual General Meeting, May 08, 2025 Sirio Pharma Co., Ltd., Annual General Meeting, May 08, 2025, at 14:30 China Standard Time. Location: The Company's Meeting Room, Shantou, Guangdong China Announcement • Mar 31
Sirio Pharma Co., Ltd. to Report Q1, 2025 Results on Apr 24, 2025 Sirio Pharma Co., Ltd. announced that they will report Q1, 2025 results on Apr 24, 2025 Announcement • Dec 31
Sirio Pharma Co., Ltd. to Report Fiscal Year 2024 Results on Apr 18, 2025 Sirio Pharma Co., Ltd. announced that they will report fiscal year 2024 results on Apr 18, 2025 Reported Earnings • Oct 24
Third quarter 2024 earnings released: EPS: CN¥1.22 (vs CN¥0.36 in 3Q 2023) Third quarter 2024 results: EPS: CN¥1.22 (up from CN¥0.36 in 3Q 2023). Revenue: CN¥1.06b (up 10% from 3Q 2023). Net income: CN¥85.3m (up 1.6% from 3Q 2023). Profit margin: 8.1% (down from 8.8% in 3Q 2023). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 15% p.a. on average during the next 3 years, compared to a 16% growth forecast for the Personal Products industry in China. Over the last 3 years on average, earnings per share has increased by 18% per year but the company’s share price has fallen by 5% per year, which means it is significantly lagging earnings. Valuation Update With 7 Day Price Move • Oct 15
Investor sentiment deteriorates as stock falls 16% After last week's 16% share price decline to CN¥27.98, the stock trades at a forward P/E ratio of 14x. Average forward P/E is 21x in the Personal Products industry in China. Total loss to shareholders of 3.5% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at CN¥15.32 per share. Valuation Update With 7 Day Price Move • Sep 30
Investor sentiment improves as stock rises 29% After last week's 29% share price gain to CN¥30.24, the stock trades at a forward P/E ratio of 16x. Average forward P/E is 20x in the Personal Products industry in China. Negligible returns to shareholders over past three years. Simply Wall St's valuation model estimates the intrinsic value at CN¥14.68 per share. Announcement • Sep 30
Sirio Pharma Co., Ltd. to Report Q3, 2024 Results on Oct 24, 2024 Sirio Pharma Co., Ltd. announced that they will report Q3, 2024 results on Oct 24, 2024 Reported Earnings • Aug 12
Second quarter 2024 earnings released: EPS: CN¥0.74 (vs CN¥0.30 in 2Q 2023) Second quarter 2024 results: EPS: CN¥0.74 (up from CN¥0.30 in 2Q 2023). Revenue: CN¥1.04b (up 23% from 2Q 2023). Net income: CN¥91.4m (up 27% from 2Q 2023). Profit margin: 8.8% (up from 8.5% in 2Q 2023). The increase in margin was driven by higher revenue. Revenue is forecast to grow 14% p.a. on average during the next 3 years, compared to a 16% growth forecast for the Personal Products industry in China. Over the last 3 years on average, earnings per share has increased by 10% per year but the company’s share price has fallen by 20% per year, which means it is significantly lagging earnings. Buy Or Sell Opportunity • Jul 31
Now 21% overvalued Over the last 90 days, the stock has fallen 23% to CN¥23.10. The fair value is estimated to be CN¥19.15, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 18% over the last 3 years, while earnings per share has been flat. Revenue is forecast to grow by 36% in 2 years. Earnings are forecast to grow by 63% in the next 2 years. Buy Or Sell Opportunity • Jul 09
Now 21% overvalued Over the last 90 days, the stock has fallen 17% to CN¥23.34. The fair value is estimated to be CN¥19.26, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 18% over the last 3 years, while earnings per share has been flat. Revenue is forecast to grow by 36% in 2 years. Earnings are forecast to grow by 63% in the next 2 years. Announcement • Jun 29
Sirio Pharma Co., Ltd. to Report First Half, 2024 Results on Aug 23, 2024 Sirio Pharma Co., Ltd. announced that they will report first half, 2024 results on Aug 23, 2024 Reported Earnings • Apr 25
First quarter 2024 earnings released: EPS: CN¥0.35 (vs CN¥0.16 in 1Q 2023) First quarter 2024 results: EPS: CN¥0.35 (up from CN¥0.16 in 1Q 2023). Revenue: CN¥951.5m (up 36% from 1Q 2023). Net income: CN¥63.0m (up 114% from 1Q 2023). Profit margin: 6.6% (up from 4.2% in 1Q 2023). The increase in margin was driven by higher revenue. Revenue is forecast to grow 15% p.a. on average during the next 3 years, compared to a 15% growth forecast for the Personal Products industry in China. Over the last 3 years on average, earnings per share has increased by 1% per year but the company’s share price has fallen by 10% per year, which means it is significantly lagging earnings. Announcement • Mar 30
Sirio Pharma Co., Ltd. to Report Q1, 2024 Results on Apr 27, 2024 Sirio Pharma Co., Ltd. announced that they will report Q1, 2024 results on Apr 27, 2024 Announcement • Dec 29
Sirio Pharma Co., Ltd. to Report Fiscal Year 2023 Results on Apr 22, 2024 Sirio Pharma Co., Ltd. announced that they will report fiscal year 2023 results on Apr 22, 2024 Reported Earnings • Oct 26
Third quarter 2023 earnings released: EPS: CN¥0.47 (vs CN¥0.37 in 3Q 2022) Third quarter 2023 results: EPS: CN¥0.47 (up from CN¥0.37 in 3Q 2022). Revenue: CN¥958.1m (up 42% from 3Q 2022). Net income: CN¥84.0m (up 27% from 3Q 2022). Profit margin: 8.8% (down from 9.8% in 3Q 2022). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 18% p.a. on average during the next 3 years, compared to a 17% growth forecast for the Personal Products industry in China. Over the last 3 years on average, earnings per share has fallen by 9% per year but the company’s share price has fallen by 24% per year, which means it is performing significantly worse than earnings. Valuation Update With 7 Day Price Move • Oct 25
Investor sentiment improves as stock rises 17% After last week's 17% share price gain to CN¥28.58, the stock trades at a forward P/E ratio of 16x. Average forward P/E is 20x in the Personal Products industry in China. Total loss to shareholders of 57% over the past three years. Reported Earnings • Aug 25
Second quarter 2023 earnings released: EPS: CN¥0.40 (vs CN¥0.54 in 2Q 2022) Second quarter 2023 results: EPS: CN¥0.40 (down from CN¥0.54 in 2Q 2022). Revenue: CN¥842.7m (up 22% from 2Q 2022). Net income: CN¥71.8m (down 25% from 2Q 2022). Profit margin: 8.5% (down from 14% in 2Q 2022). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 11% p.a. on average during the next 3 years, compared to a 17% growth forecast for the Personal Products industry in China. Over the last 3 years on average, earnings per share has fallen by 8% per year but the company’s share price has fallen by 30% per year, which means it is performing significantly worse than earnings. Announcement • Jul 01
Sirio Pharma Co., Ltd. to Report First Half, 2023 Results on Aug 25, 2023 Sirio Pharma Co., Ltd. announced that they will report first half, 2023 results on Aug 25, 2023 Announcement • Jun 02
Sirio Pharma Co., Ltd. Announces Implementation of Cash Dividend for the Year 2022, Payable on June 07, 2023 Sirio Pharma Co., Ltd. announced implemented final profit distribution of Cash dividend/10 A shares (tax included) is CNY 3.50000000 for the year 2022. Record date: 06 June 2023; Ex-date: 07 June 2023; Payment date: 07 June 2023. Reported Earnings • Apr 22
Full year 2022 earnings released: EPS: CN¥1.18 (vs CN¥1.29 in FY 2021) Full year 2022 results: EPS: CN¥1.18 (down from CN¥1.29 in FY 2021). Revenue: CN¥2.51b (up 5.8% from FY 2021). Net income: CN¥212.3m (down 8.4% from FY 2021). Profit margin: 8.5% (down from 9.8% in FY 2021). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 21% p.a. on average during the next 2 years, compared to a 17% growth forecast for the Personal Products industry in China. Over the last 3 years on average, earnings per share has remained flat but the company’s share price has increased by 13% per year, which means it is well ahead of earnings. Valuation Update With 7 Day Price Move • Dec 07
Investor sentiment improved over the past week After last week's 20% share price gain to CN¥35.78, the stock trades at a forward P/E ratio of 23x. Average forward P/E is 24x in the Personal Products industry in China. Total returns to shareholders of 46% over the past three years. Board Change • Nov 16
Less than half of directors are independent There are 5 new directors who have joined the board in the last 3 years. Of these new board members, 3 were independent directors. The company's board is composed of: 3 independent directors. 4 non-independent directors. Independent Director Guilong Zhu was the last independent director to join the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity. Reported Earnings • Oct 27
Third quarter 2022 earnings released: EPS: CN¥0.37 (vs CN¥0.30 in 3Q 2021) Third quarter 2022 results: EPS: CN¥0.37 (up from CN¥0.30 in 3Q 2021). Revenue: CN¥676.9m (up 16% from 3Q 2021). Net income: CN¥66.3m (up 21% from 3Q 2021). Profit margin: 9.8% (in line with 3Q 2021). Revenue is forecast to grow 16% p.a. on average during the next 3 years, compared to a 20% growth forecast for the Personal Products industry in China. Valuation Update With 7 Day Price Move • Sep 01
Investor sentiment improved over the past week After last week's 17% share price gain to CN¥34.00, the stock trades at a forward P/E ratio of 22x. Average forward P/E is 23x in the Personal Products industry in China. Total loss to shareholders of 25% over the past year. Simply Wall St's valuation model estimates the intrinsic value at CN¥15.41 per share. Reported Earnings • Aug 27
Second quarter 2022 earnings released: EPS: CN¥0.54 (vs CN¥0.49 in 2Q 2021) Second quarter 2022 results: EPS: CN¥0.54 (up from CN¥0.49 in 2Q 2021). Revenue: CN¥690.1m (up 5.0% from 2Q 2021). Net income: CN¥95.3m (up 7.8% from 2Q 2021). Profit margin: 14% (in line with 2Q 2021). Over the next year, revenue is forecast to grow 25%, compared to a 28% growth forecast for the Personal Products industry in China. Buying Opportunity • Aug 10
Now 23% undervalued Over the last 90 days, the stock is up 21%. The fair value is estimated to be CN¥37.98, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 3.0% over the last year. Earnings per share has declined by 29%. Revenue is forecast to grow by 40% in 2 years. Earnings is forecast to grow by 68% in the next 2 years. Buying Opportunity • Jul 15
Now 20% undervalued Over the last 90 days, the stock is up 10%. The fair value is estimated to be CN¥37.59, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 3.0% over the last year. Earnings per share has declined by 29%. Revenue is forecast to grow by 40% in 2 years. Earnings is forecast to grow by 68% in the next 2 years. Valuation Update With 7 Day Price Move • Jul 01
Investor sentiment improved over the past week After last week's 15% share price gain to CN¥31.22, the stock trades at a forward P/E ratio of 21x. Average forward P/E is 27x in the Personal Products industry in China. Total loss to shareholders of 37% over the past year. Simply Wall St's valuation model estimates the intrinsic value at CN¥35.89 per share. Buying Opportunity • Jun 30
Now 21% undervalued after recent price drop Over the last 90 days, the stock is down 2.4%. The fair value is estimated to be CN¥35.61, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 3.0% over the last year. Earnings per share has declined by 29%. Revenue is forecast to grow by 40% in 2 years. Earnings is forecast to grow by 68% in the next 2 years. Board Change • Apr 27
Less than half of directors are independent There are 5 new directors who have joined the board in the last 3 years. Of these new board members, 3 were independent directors. The company's board is composed of: 3 independent directors. 4 non-independent directors. Independent Director Guilong Zhu was the last independent director to join the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity. Reported Earnings • Apr 15
First quarter 2022 earnings released: EPS: CN¥0.08 (vs CN¥0.32 in 1Q 2021) First quarter 2022 results: EPS: CN¥0.08 (down from CN¥0.32 in 1Q 2021). Revenue: CN¥421.2m (down 17% from 1Q 2021). Net income: CN¥14.6m (down 75% from 1Q 2021). Profit margin: 3.5% (down from 11% in 1Q 2021). The decrease in margin was driven by lower revenue. Over the next year, revenue is forecast to grow 41%, compared to a 27% growth forecast for the industry in China. Buying Opportunity • Apr 15
Now 23% undervalued after recent price drop Over the last 90 days, the stock is down 42%. The fair value is estimated to be CN¥34.54, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 3.0% over the last year. Earnings per share has declined by 29%. Revenue is forecast to grow by 41% in a year. Earnings is forecast to grow by 112% in the next year. Valuation Update With 7 Day Price Move • Mar 11
Investor sentiment deteriorated over the past week After last week's 16% share price decline to CN¥29.15, the stock trades at a forward P/E ratio of 15x. Average forward P/E is 25x in the Personal Products industry in China. Total loss to shareholders of 49% over the past year. Simply Wall St's valuation model estimates the intrinsic value at CN¥27.08 per share. Valuation Update With 7 Day Price Move • Jan 26
Investor sentiment deteriorated over the past week After last week's 17% share price decline to CN¥37.53, the stock trades at a forward P/E ratio of 19x. Average forward P/E is 26x in the Personal Products industry in China. Total loss to shareholders of 49% over the past year. Simply Wall St's valuation model estimates the intrinsic value at CN¥28.72 per share. Valuation Update With 7 Day Price Move • Nov 03
Investor sentiment improved over the past week After last week's 18% share price gain to CN¥46.51, the stock trades at a forward P/E ratio of 22x. Average forward P/E is 24x in the Personal Products industry in China. Total loss to shareholders of 30% over the past year. Simply Wall St's valuation model estimates the intrinsic value at CN¥29.77 per share. Reported Earnings • Oct 28
Third quarter 2021 earnings released: EPS CN¥0.30 (vs CN¥0.34 in 3Q 2020) The company reported a soft third quarter result with weaker earnings and profit margins, although revenues improved. Third quarter 2021 results: Revenue: CN¥582.9m (up 8.4% from 3Q 2020). Net income: CN¥54.6m (down 12% from 3Q 2020). Profit margin: 9.4% (down from 12% in 3Q 2020). The decrease in margin was driven by higher expenses. Reported Earnings • Aug 27
Second quarter 2021 earnings released: EPS CN¥0.49 (vs CN¥0.41 in 2Q 2020) The company reported a solid second quarter result with improved earnings and revenues, although profit margins were flat. Second quarter 2021 results: Revenue: CN¥657.5m (up 18% from 2Q 2020). Net income: CN¥88.4m (up 19% from 2Q 2020). Profit margin: 13% (in line with 2Q 2020). Valuation Update With 7 Day Price Move • Jul 31
Investor sentiment improved over the past week After last week's 17% share price gain to CN¥64.46, the stock trades at a trailing P/E ratio of 44x. Average trailing P/E is 41x in the Personal Products industry in China. Total loss to shareholders of 2.5% over the past year. Valuation Update With 7 Day Price Move • Jun 24
Investor sentiment improved over the past week After last week's 16% share price gain to CN¥52.12, the stock trades at a trailing P/E ratio of 35.5x. Average trailing P/E is 46x in the Personal Products industry in China. Total returns to shareholders of 19% over the past year. Reported Earnings • Apr 28
Full year 2020 earnings released: EPS CN¥2.14 (vs CN¥1.46 in FY 2019) The company reported a strong full year result with improved earnings, revenues and profit margins. Full year 2020 results: Revenue: CN¥2.07b (up 31% from FY 2019). Net income: CN¥257.4m (up 81% from FY 2019). Profit margin: 13% (up from 9.0% in FY 2019). The increase in margin was driven by higher revenue. Is New 90 Day High Low • Mar 16
New 90-day low: CN¥83.31 The company is down 11% from a price of CN¥93.50 on 16 December 2020. Underperformed the Chinese market, which is down 2.0% over the last 90 days. Lagged the Personal Products industry, which is down 6.0% over the same period. Is New 90 Day High Low • Jan 18
New 90-day high: CN¥113 The company is up 6.0% from its price of CN¥106 on 21 October 2020. The Chinese market is up 7.0% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Personal Products industry, which is down 3.0% over the same period. Valuation Update With 7 Day Price Move • Jan 17
Investor sentiment improved over the past week After last week's 17% share price gain to CN¥107, the stock is trading at a trailing P/E ratio of 50x, up from the previous P/E ratio of 42.6x. This compares to an average P/E of 45x in the Personal Products industry in China. Total returns to shareholders over the past year are 171%. Is New 90 Day High Low • Dec 24
New 90-day low: CN¥84.38 The company is down 6.0% from its price of CN¥89.55 on 25 September 2020. The Chinese market is up 5.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Personal Products industry, which is up 9.0% over the same period. Is New 90 Day High Low • Dec 01
New 90-day low: CN¥86.60 The company is down 24% from its price of CN¥114 on 02 September 2020. The Chinese market is down 3.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Personal Products industry, which is down 12% over the same period. Reported Earnings • Oct 29
Third quarter earnings released Over the last 12 months the company has reported total profits of CN¥209.2m, up 13% from the prior year. Total revenue was CN¥1.87b over the last 12 months, up 15% from the prior year. Valuation Update With 7 Day Price Move • Oct 13
Market bids up stock over the past week After last week's 18% share price gain to CN¥103, the stock is trading at a trailing P/E ratio of 56.4x, up from the previous P/E ratio of 47.7x. This compares to an average P/E of 51x in the Personal Products industry in China.